Major Clinical Trials on the Horizon: What Late-2026 Drug Readouts Could Mean for Patient Access and Public Health

A promising new lung cancer drug reduced the risk of death by 34% in clinical trials. The company developing it won't say what it will charge American patients. That gap—between medical breakthrough and price tag silence—defines the next wave of pharmaceutical innovation heading toward pivotal trial results in late 2026. Ten major biotech and pharma clinical trials with key readouts are expected in the second half of 2026, spanning Alzheimer's disease, lung cancer, infectious disease prevention, chronic spontaneous urticaria, and inflammatory bowel disease.

But scientific success is only half the equation. Approximately 50% of new prescriptions for novel medicines go unfilled due to access barriers such as lack of insurance coverage, high costs, and drug shortages, and only 29% of patients remain on therapy after one year. The real test for these drugs won't just be whether they work, but whether families can afford them and whether the healthcare system can deliver them equitably.

The Drugs That Could Change Everything—If You Can Get Them

Summit Therapeutics and Akeso's ivonescimab, a bispecific PD-1×VEGF antibody, reduced the risk of death by 34% compared to standard treatment in the phase III HARMONi-6 trial for first-line squamous non-small cell lung cancer. Ivonescimab plus chemotherapy achieved a median overall survival of 27.9 months compared to 23.7 months with standard PD-1 inhibitor plus chemotherapy.

Summit has an accepted biologics license application for ivonescimab plus chemotherapy in EGFR-mutant NSCLC, with an FDA decision expected by November 14, 2026—the first China-originated oncology drug featured in an ASCO plenary session. But Summit has not publicly disclosed specific pricing figures or detailed reimbursement access plans, and explicitly states it will not make the drug available through expanded or early access until efficacy and safety are fully demonstrated. That silence on pricing while trumpeting clinical success is a pattern patients have learned to recognize—and to fear.

Bristol Myers Squibb's ADEPT-2 trial is testing Cobenfy (KarXT) for psychosis associated with Alzheimer's disease dementia, with major data readouts expected by the end of 2026. Cobenfy is a muscarinic receptor agonist combining xanomeline and trospium chloride already approved for schizophrenia, and the ADEPT program is evaluating it for hallucinations and delusions in Alzheimer's—symptoms that devastate families and drive nursing home placements. Its list price is $22,500 per year in the United States. And Bristol Myers Squibb has shown it's willing to play hardball with regulators. Adam Lenkowsky, Bristol Myers Squibb Chief Commercial Officer, stated the company is "prepared to make the difficult decision to walk away if NICE cannot recognise the value of our medicine," signaling potential pricing battles ahead.

Celldex completed enrollment of 1,939 patients across 43 countries in its Phase 3 program for barzolvolimab in chronic spontaneous urticaria—the largest program conducted in antihistamine-refractory CSU—with topline data expected in Q4 2026. Phase 2 data showed complete response rates of up to 51.1% at 150 mg compared to 6.4% for placebo.

Cidara Therapeutics reached target enrollment of 6,000 participants in its Phase 3 ANCHOR trial evaluating CD388 for prevention of seasonal influenza in high-risk populations, with an interim analysis planned for Q1 2026. CD388 is a non-vaccine preventative administered as a single 450-mg subcutaneous dose targeting immune-compromised individuals, those with comorbidities, and adults over 65, and it received FDA Breakthrough Therapy designation for universal flu protection.

Other notable trials include J&J's Rybrevant-Lazcluze combination, which achieved median overall survival nearing three and a half years in EGFR-mutant NSCLC, and BMS/BioNTech's pumitamig showing a 70% overall response rate in Phase II lung cancer trials.

The Affordability Crisis Waiting at the Pharmacy Counter

Net drug spending in the U.S. grew 10.6% from 2024 to 2025, driven largely by uptake of innovative and specialty therapies, with growth projected to continue at 4.5%–7.5% annually through 2030. Pharmaceutical companies call this "the cost of innovation." Patients call it the reason 27–28% of Americans don't fill prescriptions due to cost, and nearly two-thirds of prescriptions for newly launched drugs go unfilled in their first year.

These aren't just statistics. They're families making impossible choices between medication and groceries.

High cancer drug prices, limited insurance benefits, and complex coverage rules create major barriers to access and lead to substantial financial toxicity, with insured patients often facing high deductibles, copays, coverage denials, restrictive formularies, and administrative hurdles like prior authorization and step therapy. Fifty-four percent of adults with commercial insurance were told their plan would no longer cover medications for a chronic or rare disease, with many routed to third-party alternative funding programs that can delay access and increase out-of-pocket costs.

Cancer patient advocates warn that "drugs don't work if people can't afford them" and that affordability means "more than a price tag—it means access, dignity, and a real pathway to healing". Dr. Steve Miller, Chief Medical Officer at Express Scripts, warns that drug prices for large patient populations have become "unprecedented and unreasonable," with list prices exceeding $84,000 creating unsustainable financial pressure on insurers.

The tension is real. Insurers genuinely face unsustainable cost growth, but their response—prior authorizations, formulary restrictions, step therapy—shifts the burden onto patients least equipped to bear it.

The Infrastructure Gap That Could Block Access

Insurers only cover drugs on their formulary, and tier placement determines cost; specialty drugs in Tier 4 often have the highest out-of-pocket responsibility, and prior authorization and step-therapy protocols can delay or block access to needed medications. Rising spending on specialty drugs is driving insurers to use coverage denials and external sourcing arrangements that further complicate timely treatment.

Cancer patient advocates emphasize that "affordability doesn't end with a screening or a diagnosis. Even when patients can access care, too many are still unable to complete treatment because of financial strain". Key voices urge state and federal leaders to prioritize affordability so that cost is not a barrier to prevention, detection, treatment, and survivorship.

Advocates warn that federal policy erosion and deep Medicaid cuts are creating a looming health care cliff that threatens patient access to cancer treatments. They stress that expanding paid family and medical leave and prohibiting copay accumulator adjustment programs are critical to ensuring patients can attend appointments and complete treatment without risking their income or jobs. A June 2026 Capitol Hill event led by the Community Oncology Alliance brought together patient groups working to protect access to affordable lung cancer and cancer care, emphasizing the burden of out-of-pocket costs for targeted therapies and calling for Medicare drug affordability reforms.

Why 2026 Represents a Research Turning Point

BioPharma Dive identified these ten major trials following recent scientific progress in pancreatic cancer, hepatitis B, and obesity that is contributing to an upswing in the biotechnology sector. PwC's midyear outlook notes that pharma and life sciences deal momentum is strong heading into the second half of 2026, with capital flowing toward differentiated biopharma assets with near-term clinical and commercial catalysts in cardiometabolic and obesity, immunology and inflammation, oncology, rare disease, radiopharmaceuticals, and RNA medicines.

Biomarker-guided treatment strategies are expanding options for lung cancer patients, with multiple studies of targeted and immunotherapy-based regimens presented at ASCO 2026.

Summit Therapeutics co-CEOs Robert W. Duggan and Dr. Maky Zanganeh state their goal is to "make a meaningful difference for the betterment of patients' lives," but the company has not disclosed pricing or reimbursement plans. Investors celebrate the momentum, but strong deal activity does not guarantee that breakthrough drugs will be priced affordably or covered equitably by insurance.

What to Watch For as Results Arrive

Medicare's Drug Price Negotiation Program began applying Maximum Fair Prices to 10 high-expenditure drugs on January 1, 2026, delivering average discounts of at least 38% off 2023 list prices and generating an estimated $6 billion in Medicare savings and $1.5 billion in patient out-of-pocket savings. Over the next several years, additional specialty medicines—including antidiabetic drugs, inhalers, kinase inhibitors, and certain Part B therapies—will enter Medicare drug price negotiation, prompting changes in formularies, tiering, and utilization management.

The pharmaceutical industry fought Medicare negotiation fiercely, but 72% of adults say there is not enough government regulation of drug prices. The question is whether Medicare negotiation will expand fast enough to cover the 2026 drug wave before manufacturers lock in premium pricing.

Patients should ask their insurers four critical questions: which drugs are covered on their formulary, what their out-of-pocket costs will be for each tier, whether step-therapy or prior authorization is required before coverage, and how to request an exception or appeal if a needed drug is denied or too expensive. If coverage is denied, patients can ask their doctor about generics, biosimilars, or alternative medications; request a tier exception; file an internal appeal; seek an external appeal if the internal review is denied; and explore patient assistance programs. But navigating this system shouldn't require a law degree. And for many patients fighting cancer or Alzheimer's, it's a burden they can't carry alone.

Experts recommend that insurers negotiate outcomes-based agreements with manufacturers, requiring rebates or full refunds if drugs don't work as advertised, and that policymakers limit out-of-pocket costs for Medicare Part D beneficiaries and exempt high-value drugs from deductibles. These reforms would shift risk back onto manufacturers and force them to stand behind their efficacy claims.

As late-2026 trial results arrive, readers should watch not only for efficacy data but for pricing announcements, insurance formulary decisions, Medicare negotiation eligibility, manufacturer patient assistance commitments, and whether policymakers are preparing coverage and access infrastructure before these drugs reach the market. The survival curves and response rates will dominate the headlines. But the number that determines whether innovation reaches your family is the one drugmakers are most reluctant to disclose: the price your pharmacist will quote when your doctor writes the prescription.